Kalohexis

Kalohexis is a clinical-stage biotechnology company focused on developing a novel class of therapeutics that harness the melanocortin system to treat metabolic disorders. Spun out from Endevica Bio in March 2026, the company leverages over a decade of expertise in melanocortin biology to reprogram the body's metabolic homeostasis. Its lead candidate, 710GO, is an oral dual MC3R/MC4R agonist entering Phase 1 trials for obesity, designed to provide durable weight loss without the muscle wasting associated with GLP-1 therapies. Additionally, Kalohexis is advancing mifomelatide (TCMCB07), a dual MC3R/MC4R antagonist currently in Phase 2 development for cancer cachexia. The company's broader pipeline targets a range of metabolic conditions, including type 2 diabetes, MASH, and sarcopenia. By resetting the body's metabolic "thermostat," Kalohexis aims to address significant unmet needs across the metabolic disease spectrum.